标准治疗-话题@MedSci - 梅斯（MedSci）

#标准治疗#

60篇内容 | 2350人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1948248, encodeId=8fa81948248ff, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=ATSIC 2016：10年的标准治疗也不能缓解持续性难治性哮喘症状？, objectType=article, longId=68635, objectId=2e956863556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e956863556, replyNumber=0, likeNumber=77, createdTime=2016-07-11, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e956863556, moduleTitle=ATSIC 2016：10年的标准治疗也不能缓解持续性难治性哮喘症状？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e956863556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948249, encodeId=ceed194824904, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高, objectType=article, longId=72401, objectId=328fe24012e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328fe24012e, replyNumber=0, likeNumber=82, createdTime=2016-10-18, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328fe24012e, moduleTitle=NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=328fe24012e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948242, encodeId=f2a019482428a, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, objectType=article, longId=55957, objectId=68175595eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68175595eff, replyNumber=0, likeNumber=51, createdTime=2016-01-18, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68175595eff, moduleTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=68175595eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948243, encodeId=a5a8194824305, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案, objectType=article, longId=59145, objectId=256459145ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=256459145ee, replyNumber=0, likeNumber=69, createdTime=2016-01-19, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=256459145ee, moduleTitle=NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=256459145ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948241, encodeId=c8e519482411a, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=J Clin Oncol：贝伐珠单抗添加到标准治疗对新诊断胶质母细胞瘤的患者生存质量没有影响, objectType=article, longId=51456, objectId=9c22514562a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c22514562a, replyNumber=0, likeNumber=99, createdTime=2015-09-23, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c22514562a, moduleTitle=J Clin Oncol：贝伐珠单抗添加到标准治疗对新诊断胶质母细胞瘤的患者生存质量没有影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c22514562a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948240, encodeId=9809194824072, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, objectType=article, longId=40492, objectId=8caf404928a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caf404928a, replyNumber=0, likeNumber=0, createdTime=2015-05-05, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caf404928a, moduleTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8caf404928a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948237, encodeId=0e0c194823eac, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=糖尿病：个体化治疗达标与标准治疗的选择--个体化更循证, objectType=article, longId=33301, objectId=f70933301c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f70933301c3, replyNumber=0, likeNumber=61, createdTime=2015-01-31, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f70933301c3, moduleTitle=糖尿病：个体化治疗达标与标准治疗的选择--个体化更循证, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f70933301c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948238, encodeId=56b319482383f, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=ASCO 2014：进展期卵巢癌：新辅助化疗创伤低于标准治疗, objectType=article, longId=36096, objectId=bd693609667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd693609667, replyNumber=0, likeNumber=61, createdTime=2014-09-24, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd693609667, moduleTitle=ASCO 2014：进展期卵巢癌：新辅助化疗创伤低于标准治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bd693609667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948233, encodeId=643c194823388, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=Gastroenterology：内镜下治疗应成为Barrett黏膜腺癌的标准治疗方法, objectType=article, longId=28499, objectId=cb2b28499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2b28499db, replyNumber=0, likeNumber=100, createdTime=2014-09-03, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2b28499db, moduleTitle=Gastroenterology：内镜下治疗应成为Barrett黏膜腺癌的标准治疗方法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cb2b28499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948239, encodeId=3d401948239ee, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=Eur Heart J：CABG仍为冠脉三支病变标准治疗方案, objectType=article, longId=36175, objectId=9848361e52d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9848361e52d, replyNumber=0, likeNumber=58, createdTime=2014-11-12, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9848361e52d, moduleTitle=Eur Heart J：CABG仍为冠脉三支病变标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9848361e52d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948234, encodeId=ba9819482343f, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=NEJM：程序化标准治疗感染性休克不降低死亡率, objectType=article, longId=32145, objectId=56423214543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56423214543, replyNumber=0, likeNumber=65, createdTime=2014-09-19, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56423214543, moduleTitle=NEJM：程序化标准治疗感染性休克不降低死亡率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=56423214543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948236, encodeId=b1b8194823613, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=JAMA：射频消融将为Barrett食管伴异型增生的标准治疗方案, objectType=article, longId=32900, objectId=70cc3290075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70cc3290075, replyNumber=0, likeNumber=64, createdTime=2015-01-22, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70cc3290075, moduleTitle=JAMA：射频消融将为Barrett食管伴异型增生的标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=70cc3290075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948235, encodeId=25db194823508, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=Lancet Oncol：低剂量放疗是惰性淋巴瘤标准治疗, objectType=article, longId=32195, objectId=19d03219540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d03219540, replyNumber=0, likeNumber=60, createdTime=2014-08-26, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d03219540, moduleTitle=Lancet Oncol：低剂量放疗是惰性淋巴瘤标准治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=19d03219540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948232, encodeId=b4a71948232cd, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案, objectType=article, longId=18507, objectId=75c41850e4b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75c41850e4b, replyNumber=0, likeNumber=73, createdTime=2013-06-24, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75c41850e4b, moduleTitle=Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=75c41850e4b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948230, encodeId=955d19482302a, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）, objectType=article, longId=11325, objectId=b81e1132569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b81e1132569, replyNumber=0, likeNumber=68, createdTime=2013-10-20, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b81e1132569, moduleTitle=标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b81e1132569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948229, encodeId=fd2b194822919, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, objectType=article, longId=10558, objectId=8e311055832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e311055832, replyNumber=0, likeNumber=142, createdTime=2012-11-21, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e311055832, moduleTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8e311055832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948231, encodeId=1db51948231f8, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=JCO:ABVD仍是进展期霍奇金淋巴瘤的标准治疗方案, objectType=article, longId=12101, objectId=dd1912101f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd1912101f8, replyNumber=0, likeNumber=74, createdTime=2013-11-07, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd1912101f8, moduleTitle=JCO:ABVD仍是进展期霍奇金淋巴瘤的标准治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dd1912101f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948227, encodeId=9d1d194822ee6, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=JCO：NSCLC标准治疗方案不应添加沙利度胺, objectType=article, longId=4084, objectId=cb3b40844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3b40844d, replyNumber=0, likeNumber=59, createdTime=2012-09-12, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3b40844d, moduleTitle=JCO：NSCLC标准治疗方案不应添加沙利度胺, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cb3b40844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948228, encodeId=b45e1948228ab, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=术前同步放化疗：直肠癌的标准治疗模式, objectType=article, longId=7565, objectId=95aae56550, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aae56550, replyNumber=0, likeNumber=63, createdTime=2012-07-28, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aae56550, moduleTitle=术前同步放化疗：直肠癌的标准治疗模式, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=95aae56550)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948226, encodeId=7d9d194822653, content=<a href='/topic/show?id=c04b6193ee0' target=_blank style='color:#2F92EE;'>#标准治疗#</a>, objectTitle=刘喆：NSCLC维持治疗是否可能成为标准治疗模式？, objectType=article, longId=3194, objectId=7cbc31942f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cbc31942f, replyNumber=0, likeNumber=57, createdTime=2012-02-16, rootId=0, userName=小小小向日葵, userId=72bf2500198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cbc31942f, moduleTitle=刘喆：NSCLC维持治疗是否可能成为标准治疗模式？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7cbc31942f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

标准治疗

2020-05-29

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

ATSIC 2016：10年的标准治疗也不能缓解持续性难治性哮喘症状？

2016-07-11

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高

2016-10-18

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案

2016-01-18

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

NEJM：HCV基因型2或3患者——sofosbuvir/velpatasvir优于标准治疗方案

2016-01-19

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

J Clin Oncol：贝伐珠单抗添加到标准治疗对新诊断胶质母细胞瘤的患者生存质量没有影响

2015-09-23

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待

2015-05-05

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

糖尿病：个体化治疗达标与标准治疗的选择--个体化更循证

2015-01-31

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

ASCO 2014：进展期卵巢癌：新辅助化疗创伤低于标准治疗

2014-09-24

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

Gastroenterology：内镜下治疗应成为Barrett黏膜腺癌的标准治疗方法

2014-09-03

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

Eur Heart J：CABG仍为冠脉三支病变标准治疗方案

2014-11-12

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

NEJM：程序化标准治疗感染性休克不降低死亡率

2014-09-19

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

JAMA：射频消融将为Barrett食管伴异型增生的标准治疗方案

2015-01-22

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

Lancet Oncol：低剂量放疗是惰性淋巴瘤标准治疗

2014-08-26

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案

2013-06-24

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）

2013-10-20

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益

2012-11-21

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

JCO:ABVD仍是进展期霍奇金淋巴瘤的标准治疗方案

2013-11-07

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

JCO：NSCLC标准治疗方案不应添加沙利度胺

2012-09-12

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

术前同步放化疗：直肠癌的标准治疗模式

2012-07-28

小小小向日葵 (审核中...)

前往app查看评论内容

#标准治疗#

刘喆：NSCLC维持治疗是否可能成为标准治疗模式？

2012-02-16

科室
- - 订阅+
  - 更多科室
工具
服务